Brief: Bioinvent Announces New Clinical Trial Collaboration

BioInvent International AB

17/07/2024 07:06

July 17 (Reuters) - BioInvent International AB
 BINV.ST :
    * BIOINVENT ANNOUNCES NEW CLINICAL TRIAL COLLABORATION AND
SUPPLY
AGREEMENT WITH MSD TO EVALUATE BI-1607 IN COMBINATION WITH
KEYTRUDA (PEMBROLIZUMAB) AND IPILIMUMAB
    * AGREEMENT TO SUPPORT EXPANSION OF BI-1607 PROGRAM WITH NEW
PHASE
2 TRIPLET COMBINATION STUDY IN METASTATIC MELANOMA
    * STUDY WILL EVALUATE ANTI-FCΓRIIB ANTIBODY BI-1607 WITH
LOW-DOSE
ANTI-CTLA-4, IPILIMUMAB, PLUS KEYTRUDA®
    * PHASE 1 DATA PREVIOUSLY DEMONSTRATED BI-1607 IS SAFE AND
WELL
TOLERATED AND ACHIEVES FULL RECEPTOR OCCUPANCY DURING TREATMENT
INTERVAL AT SEVERAL DOSE LEVELS
    * PRECLINICAL DATA SHOW BI-1607 ENABLES LOWER ANTI-CTLA-4
DOSING
WITH IMPROVED SURVIVAL

Source text for Eikon:  ID:nMFN7FyLDc 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))